Skip to main content
. 2022 Mar 4;3(2):90–94. doi: 10.1158/2643-3230.BCD-21-0203

Figure 1.

Figure 1. Clinical and laboratory features surrounding the use of emapalumab for refractory CAR T-cell–induced CRS. A, Temperature in degrees Celsius (°C). B, Ferritin in ng/mL, and CRP in mg/dL. C, Absolute neutrophil count (ANC) in cells/μL and platelets ×1,000 cells/μL. D, Fibrinogen in mg/dL and international normalized ratio (INR). E, Serum cytokine levels in pg/mL on a logarithmic scale. Expected cytokine-level elevations from previously published reports (5, 8). Asterisk (*) indicates above limit of quantification. Dagger (†) indicates below limit of quantification.

Clinical and laboratory features surrounding the use of emapalumab for refractory CAR T-cell–induced CRS. A, Temperature in degrees Celsius (°C). B, Ferritin in ng/mL, and CRP in mg/dL. C, Absolute neutrophil count (ANC) in cells/μL and platelets ×1,000 cells/μL. D, Fibrinogen in mg/dL and international normalized ratio (INR). E, Serum cytokine levels in pg/mL on a logarithmic scale. Expected cytokine-level elevations from previously published reports (5, 8). Asterisk (*) indicates above limit of quantification. Dagger (†) indicates below limit of quantification.